

Guido Bellezza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5428546/publications.pdf>

Version: 2024-02-01

46
papers

804
citations

430754

18
h-index

552653

26
g-index

46
all docs

46
docs citations

46
times ranked

1416
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 53-68.	1.0	56
2	Future options for ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, 211-219.	0.9	50
3	Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ER α . <i>Prostate</i> , 2017, 77, 196-210.	1.2	47
4	Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. <i>Lung Cancer</i> , 2015, 90, 255-260.	0.9	43
5	Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. <i>Clinical Lung Cancer</i> , 2014, 15, 86-92.	1.1	40
6	Nonalcoholic fatty liver disease impairs the cytochrome P-450-dependent metabolism of α -tocopherol (vitamin E). <i>Journal of Nutritional Biochemistry</i> , 2017, 47, 120-131.	1.9	40
7	An Additional Case of Breast Tumor Resembling the Tall Cell Variant of Papillary Thyroid Carcinoma. <i>International Journal of Surgical Pathology</i> , 2015, 23, 217-220.	0.4	29
8	Glyoxalase 2 drives tumorigenesis in human prostate cells in a mechanism involving androgen receptor and p53 β 21 axis. <i>Molecular Carcinogenesis</i> , 2017, 56, 2112-2126.	1.3	29
9	Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. <i>Medical Oncology</i> , 2018, 35, 72.	1.2	29
10	Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool. <i>Frontiers in Immunology</i> , 2020, 11, 839.	2.2	28
11	Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 159-168.	1.4	27
12	Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3701-3712.	2.9	27
13	Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. <i>Genes</i> , 2021, 12, 679.	1.0	25
14	Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. <i>Oncotarget</i> , 2015, 6, 32368-32379.	0.8	25
15	Osimertinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 257-276.	1.8	24
16	Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4403.	1.8	24
17	Current Challenges for IDO2 as Target in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 679953.	2.2	24
18	Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors. <i>Oncotarget</i> , 2018, 9, 27346-27362.	0.8	20

#	ARTICLE	IF	CITATIONS
19	Ectopic prostatic tissue in the bladder. <i>International Journal of Urology</i> , 2005, 12, 1066-1068.	0.5	19
20	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. <i>Lung Cancer</i> , 2016, 95, 82-87.	0.9	19
21	Garcinoic acid prevents A β deposition in the mouse brain. <i>Journal of Biological Chemistry</i> , 2020, 295, 11866-11876.	1.6	18
22	High expression of cellular retinol binding protein-1 in lung adenocarcinoma is associated with poor prognosis. <i>Genes and Cancer</i> , 2015, 6, 490-502.	0.6	16
23	Pigmented Pheochromocytoma of the Adrenal Gland: A Case Report and Review of the Literature. <i>Archives of Pathology and Laboratory Medicine</i> , 2004, 128, e125-e128.	1.2	16
24	IMP3 Is Strongly Expressed in Malignant Phyllodes Tumors of the Breast. <i>International Journal of Surgical Pathology</i> , 2016, 24, 37-42.	0.4	15
25	Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. <i>Clinical Drug Investigation</i> , 2018, 38, 983-987.	1.1	14
26	High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. <i>Genes</i> , 2021, 12, 273.	1.0	14
27	Schwannoma of the breast: a case report and review of the literature. <i>Tumori</i> , 2007, 93, 308-11.	0.6	11
28	Classification Model to Estimate MIB-1 (Ki 67) Proliferation Index in NSCLC Patients Evaluated With ¹⁸ F-FDG-PET/CT. <i>Anticancer Research</i> , 2020, 40, 3355-3360.	0.5	8
29	INSL4 as prognostic marker for proliferation and invasiveness in Non-Small-Cell Lung Cancer. <i>Journal of Cancer</i> , 2021, 12, 3781-3795.	1.2	8
30	KRAS mutation and DNA repair and synthesis genes in non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 689-696.	0.4	7
31	Localized Intrasplenic Mesothelioma. <i>International Journal of Surgical Pathology</i> , 2014, 22, 451-455.	0.4	6
32	Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. <i>PLoS ONE</i> , 2021, 16, e0255580.	1.1	6
33	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6
34	Primary angiosarcoma of the kidney: case report and comprehensive literature review. <i>Open Medicine (Poland)</i> , 2019, 14, 443-455.	0.6	5
35	Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2972-2980.	1.4	5
36	Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. <i>Genes</i> , 2021, 12, 992.	1.0	5

#	ARTICLE	IF	CITATIONS
37	Coexpression of HER-2/neu and p53 in Breast Cancer Identifies a Subset with an Aggressive Biopathological Profile. <i>Tumori</i> , 2006, 92, 412-415.	0.6	4
38	The implementation of a commercially available multi-gene profile test for breast cancer characterization in a department of pathology: what have we learned from the first 100 cases?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1079-1087.	1.4	3
39	Inflammatory myofibroblastic tumor of the larynx with anaplastic lymphoma kinase (ALK) protein overexpression. A case report. <i>Tumori</i> , 2006, 92, 449-51.	0.6	3
40	CD10 is frequently expressed in classical seminomas. <i>Histology and Histopathology</i> , 2014, 29, 101-6.	0.5	3
41	PLA2R Immunohistochemistry Staining in Membranous Glomerulopathy: A Challenging Stain to Interpret But a Potentially Useful Diagnostic Tool. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 414-421.	0.6	2
42	Type A thymoma invading the trachea: a case report. <i>Mediastinum</i> , 2021, 5, 0-0.	0.6	1
43	Cholesterol crystals tubulointerstitial injury during nephrotic syndrome; can be classified as tubular crystallopathy?. <i>Journal of Nephropathology</i> , 2021, 10, e20-e20.	0.1	1
44	Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. <i>Oncology and Therapy</i> , 2022, 10, 291-300.	1.0	1
45	Mitotic index matter: how to improve the assessment of mitosis in order to better classify G2 breast cancer and luminal A category. <i>Histology and Histopathology</i> , 2018, 33, 81-88.	0.5	1
46	Impact of Epithelialâ€Mesenchymal Immunophenotype on Local Aggressiveness in Papillary Thyroid Carcinoma Invading the Airway. <i>Journal of Clinical Medicine</i> , 2021, 10, 4351.	1.0	0